Brief Summary of Potential SARS-CoV-2 Prophylactic and Treatment Drugs in the Emergency Department

منو

" Brief Summary of Potential SARS-CoV-2 Prophylactic and Treatment Drugs in the Emergency Department "
Brown, Cortlyn; Noble, Jeanne; Coralic, Zlatan

Document Type	:	AL
Record Number	:	932642
Doc. No	:	LA622689zd
Language of Document	:	English
Main Entry	:	Brown, Cortlyn; Noble, Jeanne; Coralic, Zlatan
Title & Author	:	Brief Summary of Potential SARS-CoV-2 Prophylactic and Treatment Drugs in the Emergency Department [Article]\ Brown, Cortlyn; Noble, Jeanne; Coralic, Zlatan
Title of Periodical	:	Western Journal of Emergency Medicine: Integrating Emergency Care with Population Health
Volume/ Issue Number	:	21/3
Date	:	2020
Abstract	:	As of March 30th, 2020 there were 161,807 total cases and 2,953 total deaths of SARS-CoV-2 in the United States, with the number of cases expected to rise. Other than supportive care, there are no SARS-CoV-2 specific treatments available for patients discharged from the emergency department (ED) or those admitted to the hospital. In addition, there are no vaccines available to protect our at-risk healthcare workers. The National Institutes of Health is conducting a Phase 1 clinical trial to evaluate for a potential vaccine and the recipients have started to receive the investigational vaccine.2 We present a brief overview of the potential prophylactic and treatment agents under investigation, some which could be initiated in the ED if proven effective.